Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study monitors SPINRAZA's impact on movement in adults with SMA type II

NCT ID NCT04159987

First seen Dec 08, 2025 · Last updated May 22, 2026 · Updated 25 times

Summary

This study follows 20 adults with spinal muscular atrophy (SMA) type II who are already taking SPINRAZA, a drug given via spinal injection. Researchers will measure changes in motor function, like sitting, standing, and arm movement, over 27 months. The goal is to see if the drug helps maintain or improve physical abilities in this group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SPINAL MUSCULAR ATROPHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • APHP

    Paris, Île-de-France Region, 94000, France

  • CHRU de Lille

    Lille, Hauts-de-France, 59000, France

  • CHU de Lyon

    Lyon, Auvergne-Rhône-Alpes, 69677, France

  • CHU de Montpellier

    Montpellier, Occitanie, 34090, France

  • CHU de Nice

    Nice, Provence-Alpes-Côte d'Azur Region, 06000, France

  • CHU de Toulouse

    Toulouse, Occitanie, 31059, France

  • Hopital de la Timone - APHM

    Marseille, Provence-Alpes-Côte d'Azur Region, 13005, France

Conditions

Explore the condition pages connected to this study.